Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany
Rapid Micro Biosystems has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany for $0.75 per share in an all-cash tender offer. Following the transaction, which is expected to close in December 2026, Rapid Micro Biosystems will become a wholly owned subsidiary of Merck KGaA's Life Science business. The deal aims to expand the reach of the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.
Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany
Rapid Micro Biosystems has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The acquisition will be conducted via a tender offer and aims to accelerate the global adoption of Rapid's Growth Direct platform within Merck's Life Science business.
Counterparty
Merck KGaA, Darmstadt, Germany
“We are pleased to report 22% third quarter total revenue growth driven by both our Product and Service businesses. I am also particularly pleased with the continued progress in our gross margin expansion initiatives, which resulted in a third quarter total gross margin of 25%, including record Product and Service gross margins.”
Rob Spignesi, President and CEO
“I'm incredibly proud of what the Rapid Micro team has accomplished and the impact the Growth Direct platform is having across pharmaceutical manufacturing globally. Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany centered on a shared commitment to innovation and helping customers modernize quality control workflows. We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct's reach, accelerate adoption of the Growth Direct platform and more fully serve our combined global customer base.”